Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06128551 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 55 to 56 Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 1 of 14 entries · Publications: details revised at 1 of 1 entry Show 3 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 14 entries
    • Publications: details revised at 1 of 1 entry
  2. Study sites: 53 to 55v12
  3. Site details revised at 1 of 53 sitesv11
  4. Phase: Phase 1 to Phase 1/2 Enrollment target: 210 to 534 · Primary completion date: Nov 30, 2026 to Dec 2028 · Primary endpoints: 2 to 6 · 8 morev10 Show 11 more changesShow less
    • Enrollment target: 210 to 534
    • Primary completion date: Nov 30, 2026 to Dec 2028
    • Primary endpoints: 2 to 6
    • Study sites: 54 to 53
    • Completion date: Nov 30, 2026 to Jun 2029
    • Interventions: Assigned interventions (Drug) to Daraxonrasib (Drug), Elironrasib (Drug)
    • Eligibility criteria shortened, about 30 words
    • Secondary endpoints: 10 to 14
    • Study description expanded, about 15 words
    • Study arms: 1 to 3
    • Study title expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites revised (54)v9 See this version in full on ClinicalTrials.gov ↗
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 28 to 54v8
  2. Study sites: 16 to 28v7
  3. Study sites: 14 to 16v6
  4. Study sites: 13 to 14v5
  5. Study sites: 7 to 13v4
  6. Study sites: 3 to 7v3
  7. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 15, 2023 to Nov 14, 2023 · Site details revised at 3 of 3 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 15, 2023 to Nov 14, 2023
    • Site details revised at 3 of 3 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Revolution Medicines, Inc.
16 trials monitored
See 1 trial at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 1 more disease
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Trial Details
NCT Number NCT06128551
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Enrollment 534 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov